8-K: XOMA Royalty to Acquire Generation Bio in Cash and CVR Deal

XOMA Royalty Corporation will acquire Generation Bio Co. for $4.2913 per share in cash plus one contingent value right, with the deal expected to close in February 2026.

Summary

• XOMA Royalty Corporation (Parent) and its wholly owned subsidiary, XRA 7 Corp. (Merger Sub), have entered into an Agreement and Plan of Merger to acquire Generation Bio Co.
• The Offer Price for each Generation Bio share is $4.2913 in cash, without interest, plus one non-transferable Contingent Value Right (CVR).
• The Buyer Entities will commence a tender offer within 15 business days, which will remain open for 20 business days, subject to extension.
• Following the tender offer, Merger Sub will merge into Generation Bio, with Generation Bio continuing as the surviving corporation and a wholly owned subsidiary of Parent. The merger is expected to close in or around February 2026, without a stockholder vote, pursuant to Section 251(h) of the DGCL.
• CVRs represent the right to receive potential cash payments from: (i) net cash at closing exceeding $28.97 million, (ii) savings realized from Generation Bio's Cambridge office lease obligations, (iii) proceeds from Generation Bio's existing license agreement with ModernaTX, Inc. (Moderna Collaboration), and (iv) proceeds from out-licensing or sale of Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform (Legacy Assets).
• Payments from Moderna Collaboration and Legacy Assets will be on a declining sliding scale over a 10-year CVR period, starting at up to 90% and 70% respectively.
• Generation Bio's Board of Directors unanimously approved the Merger Agreement and recommends that stockholders accept the Offer and tender their shares.
• Stockholders, including Atlas Venture entities, Jason Rhodes, and Geoff McDonough, collectively owning approximately 15.38% of outstanding shares, have signed support agreements to tender their shares.
• In-the-Money Options will become fully vested and converted into cash based on the Cash Amount minus the exercise price. Out-of-the-Money Options will be cancelled for no consideration.
• Unvested restricted stock unit awards will become fully vested and settled into Company Common Stock, which will then be converted into the Offer Price at the Effective Time.
• Generation Bio's 2020 Employee Stock Purchase Plan (ESPP) will terminate immediately prior to the Effective Time, with no new offering period commencing after the Agreement Date.

Sentiment

Score: 7

Explanation: The acquisition provides a clear exit for Generation Bio stockholders with a fixed cash component and potential upside via CVRs. While CVRs introduce uncertainty, the overall transaction is structured to provide value from existing assets and collaborations, which is positive given Generation Bio's 'Wind-Down Process.' The unanimous board approval and significant stockholder support further bolster the positive sentiment for the transaction's completion.

Positives

• Provides a clear exit strategy for Generation Bio stockholders with a fixed cash component of $4.2913 per share.
• Offers potential additional cash upside through Contingent Value Rights (CVRs) tied to net cash, lease savings, the Moderna collaboration, and monetization of the ctLNP delivery platform.
• The transaction received unanimous approval and recommendation from Generation Bio's Board of Directors, indicating strong internal support.
• Significant stockholder commitment, with approximately 15.38% of outstanding shares already pledged to tender, enhances deal certainty.
• The tender offer is not subject to a financing condition, reducing financial risk for the transaction's completion.
• In-the-Money stock options will be fully vested and converted into cash, providing liquidity to option holders.
• Unvested restricted stock unit awards will fully vest and be settled into common stock, which will then receive the Offer Price.

Negatives

• Contingent Value Rights (CVRs) are highly speculative, and there is no assurance that any CVR payments will be received.
• CVRs are non-transferable except under limited circumstances, significantly limiting liquidity for holders.
• Out-of-the-Money stock options will be cancelled for no consideration, resulting in a loss for holders of such options.
• The company is undergoing a 'Wind-Down Process' for its operations and research and development activities, indicating the cessation of its core business as an independent entity.
• The company will be delisted from Nasdaq and deregistered under the Exchange Act, ending its public trading status.

Risks

• The proposed transactions may not be completed in a timely manner, or at all, which could adversely affect Generation Bio's business and stock price.
• Various closing conditions of the Offer or the Merger may not be satisfied or waived.
• Uncertainty exists regarding how many of Generation Bio's stockholders will tender their shares in the Offer.
• There is a risk that competing offers or acquisition proposals for Generation Bio may emerge.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Merger Agreement.
• Uncertainty surrounds the ultimate transaction costs associated with the acquisition.
• There is a significant risk that no CVR Payments will be made under the CVR Agreement.
• The announcement or pendency of the proposed transactions could negatively impact Generation Bio's trading price, business, operating results, and relationships with collaborators, vendors, competitors, and employees.
• Stockholder litigation or legal proceedings related to the proposed transactions may result in significant costs of defense, indemnification, and liability, or present risks to the timing or certainty of the closing.
• Changes in Generation Bio's businesses during the period between the announcement and closing of the proposed transactions could occur.
• Uncertainties pertaining to broader industry, market, economic, political, or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates, and policies could affect the transaction.

Future Outlook

The acquisition is expected to integrate Generation Bio's potential milestone and royalty payments from its existing collaboration with ModernaTX, Inc. and its cell-targeted lipid nanoparticles (ctLNP) delivery platform into XOMA Royalty's portfolio. CVR holders have the potential to receive additional payments from these future monetizations, as well as from net cash exceeding a specified threshold and savings from the Cambridge office lease. However, the realization of CVR payments is highly speculative and not guaranteed, with no assurance that any such payments will be received.

Management Comments

• Generation Bio's board of directors has determined that the acquisition by XOMA Royalty is in the best interests of all Generation Bio stockholders and has unanimously approved the Merger Agreement.

Industry Context

XOMA Royalty Corporation operates as a biotechnology royalty aggregator, specializing in acquiring future economics from pre-commercial and commercial therapeutic candidates. This acquisition of Generation Bio, a company historically focused on T cell-driven autoimmune diseases using its ctLNP delivery platform, aligns with XOMA Royalty's strategy to expand its portfolio by incorporating existing collaboration agreements (like with Moderna) and valuable intellectual property assets. The transaction reflects a trend where specialized aggregators seek to extract value from biotech companies, particularly those undergoing strategic shifts or winding down core operations, by monetizing their intellectual property and contractual rights.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions the risk of 'stockholder litigation or legal proceedings in connection with the proposed transactions' that may result in significant costs or affect the timing/certainty of closing. It also refers to 'any legal proceedings that commenced prior to the Offer Closing Time' as part of estimated post-merger closing costs, but no specific ongoing litigation is detailed.

Related Party Transactions

• Atlas Venture Fund X, L.P., Atlas Venture Associates X, L.P., Atlas Venture Associates X, LLC, Jason Rhodes, and Geoff McDonough (collectively, the Support Stockholders), owning approximately 15.38% of outstanding Company Shares, entered into Tender and Support Agreements with Parent and Merger Sub. These agreements commit them to tender their shares in the Offer and support the merger.

Stakeholder Impact

• Shareholders: Will receive a fixed cash payment per share and contingent value rights (CVRs). CVRs offer potential upside but are non-transferable and speculative. The company's delisting will end public trading of its shares.
• Employees: In-the-Money stock options will be cashed out, and unvested restricted stock units will vest and convert to the Offer Price. The ESPP will terminate. There may be changes in employment as the company undergoes a 'Wind-Down Process' for its operations and R&D activities.
• Customers/Collaborators: The existing Collaboration and License Agreement with ModernaTX, Inc. is a key asset, with proceeds contributing to potential CVR payments. The ctLNP delivery platform is also targeted for monetization.
• Creditors: Existing monetary liabilities and contractual obligations are factored into the calculation of Closing Net Cash, which impacts potential CVR payments.
• Management: Current directors and officers will be replaced by those of Merger Sub post-merger. Indemnification rights and D&O tail policies will be maintained for former directors and officers.

Next Steps

• Buyer Entities to commence a tender offer for all outstanding shares of Generation Bio common stock within 15 business days of the Agreement Date.
• Generation Bio to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The tender offer will remain open for 20 business days, subject to extension under certain circumstances.
• Merger Sub will irrevocably accept for payment and pay for all validly tendered shares promptly after the offer's expiration.
• The Merger is expected to close in or around February 2026, following the consummation of the tender offer.
• The Surviving Corporation will cause Generation Bio's securities to be delisted from Nasdaq and deregistered under the Exchange Act as promptly as practicable after the Effective Time.
• Parent will recalculate the Final Net Cash within 120 days following the Merger Closing Date.
• Parent will use commercially reasonable efforts to pursue Legacy Assets Transactions during the Legacy Assets Transaction Period (five years following the Closing Date).
• Parent will comply with all obligations under the Moderna Collaboration and any Legacy Assets Transaction Agreements.

Key Dates

Recommendation

The definitive merger agreement provides a fixed cash price per share, offering certainty to investors. The inclusion of Contingent Value Rights (CVRs) offers potential upside from future monetization of legacy assets and the Moderna collaboration, but these payments are highly speculative and not guaranteed. Given the company's 'Wind-Down Process' and the non-transferable nature of the CVRs, a 'Hold' recommendation is appropriate for existing shareholders to realize the cash value and await any potential CVR payments, while new investors would find the CVRs' illiquidity and speculative nature less attractive for a 'Buy' recommendation. The deal is already structured, limiting significant price movement beyond the offer price unless a superior proposal emerges.

Keywords

XOMA Royalty, Generation Bio, Merger, Acquisition, Tender Offer, Contingent Value Rights, CVR, Biotechnology, Royalty Aggregator, ctLNP, siRNA, Moderna Collaboration, Legacy Assets, SEC Filing, Corporate Action